Axxam Announces Two Discovery Collaboration Agreements with Boehringer Ingelheim
News Jan 31, 2007
The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening and lead optimization through the joint efforts of Axxam and Boehringer Ingelheim researchers.
The second agreement covers the transfer of protein material and a corresponding specific functional assay for high-throughput screening to Boehringer Ingelheim.
“Axxam is proud to partner with Boehringer Ingelheim to advance their drug discovery program,” said Dr. Stefan Lohmer, Chairman and Chief Executive Officer at Axxam.
“These two agreements recognize our reputation as a quality provider of key components of early-stage drug discovery – gene expression and functional assay development for high-throughput screening.”
Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.
Further financial details of the agreements are not disclosed.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.